High-Dose Chemotherapy and Autologous Stem Cell Transplant

Nabil Adra; Rafat Abonour

doi:10.1016/j.ucl.2019.04.007

High-Dose Chemotherapy and Autologous Stem Cell Transplant

Urol Clin North Am. 2019 Aug;46(3):439-448. doi: 10.1016/j.ucl.2019.04.007. Epub 2019 May 14.

Authors

Nabil Adra¹, Rafat Abonour²

Affiliations

¹ Division of Hematology & Medical Oncology, Melvin & Bren Simon Cancer Center, Indiana University School of Medicine, 535 Barnhill Drive, RT 400, Indianapolis, IN 46202, USA. Electronic address: nadra@iu.edu.
² Division of Hematology & Medical Oncology, Melvin & Bren Simon Cancer Center, Indiana University School of Medicine, 535 Barnhill Drive, RT 400, Indianapolis, IN 46202, USA.

PMID: 31277738
DOI: 10.1016/j.ucl.2019.04.007

Abstract

Germ cell tumors (GCT) are the most common cancer in men between 15 and 35 years of age and the incidence has increased during the past several decades. This article reviews the current knowledge on high-dose chemotherapy (HDCT) and stem cell transplant for salvage treatment of patients with relapsed metastatic GCT. Furthermore, the authors attempt to dissect the controversy of using standard-dose versus high-dose therapy as initial salvage and identify patients who are most likely to benefit from HDCT and peripheral blood stem cell transplant.

Keywords: Germ cell tumor; High-dose chemotherapy; Salvage chemotherapy; Stem cell transplant; Testicular cancer.

Publication types

Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Combined Modality Therapy
Humans
Male
Neoplasm Recurrence, Local / therapy
Neoplasms, Germ Cell and Embryonal / pathology
Neoplasms, Germ Cell and Embryonal / therapy*
Salvage Therapy
Stem Cell Transplantation*
Testicular Neoplasms / pathology
Testicular Neoplasms / therapy*
Transplantation, Autologous